Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Hemispherx Biopharma Inc (NYSE MKT LLC:HEB)

Delayed Data
As of 4:01pm ET
 -0.0508 / -2.55%
Today’s Change
Today|||52-Week Range

Company Description

Hemispherx Biopharma, Inc. is a biopharmaceutical company, which engages in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based disorders. Its products include Alferon N Injection and the experimental immunotherapeutic/antiviral Ampligen. Alferon N Injection is a purified, natural source, glycosylated, multispecies alpha interferon product, composed of eight forms of high-purified alpha interferon. Ampligen includes application as a treatment for Chronic Fatigue Syndrome and as a vaccine enhancer for therapeutic and/or preventative development related to influenza and cancer treatments. The company was founded in August 1966 and is headquartered in Philadelphia, PA.

Contact Information

Hemispherx Biopharma, Inc.
One Penn Center
Philadelphia Pennsylvania 19103
P:(215) 988-0080
Investor Relations:



Other institutional3.28%
Mutual fund holders2.63%
Individual stakeholders2.21%

Top Executives

Thomas Kenwood EquelsPresident, CEO, Secretary & General Counsel
Wayne S. SpringateSenior Vice President-Operations
Adam PascaleChief Financial & Accounting Officer
David R. StrayerChief Scientific & Medical Officer
Carol A. SmithQuality Manager